LL10新型长效局麻药在健康志愿者中的I期安全性、耐受性、疗效及药代动力学研究
LL10由QX-OH 1.26%与左布比卡因0.325%组成,此项首次人体试验在健康志愿者中评估三种给药途径的安全性、耐受性、疗效和药代动力学,并与安慰剂及左布比卡因对照。137例受试者均未出现严重不良事件,LL10呈线性药代动力学,1.26%/0.325%浓度在股神经阻滞中较左布比卡因0.325%延长阻滞持续时间。
要点
- 137例受试者均未发生严重不良事件,TAPB后出现剂量依赖性全身不良事件且均自行缓解。
- LL10呈线性药代动力学,健康志愿者耐受剂量可达40 ml(相当于7/1.81 mg kg-1)。
- 1.26%/0.325% LL10在股神经阻滞中较左布比卡因0.325%延长阻滞持续时间。
核心结论
- 1.26%/0.325% LL10在健康志愿者中耐受性良好,剂量可达40 ml(相当于7/1.81 mg kg-1)。
- LL10在股神经阻滞中较左布比卡因0.325%产生更长的局部麻醉持续时间,但在皮下浸润或腹横肌平面阻滞中未显示延长。
研究设计与样本
- I期单中心、安慰剂和左布比卡因对照研究,在健康志愿者中评估LL10的安全性、耐受性、疗效和药代动力学。
- 共纳入137例受试者,考察皮下浸润、股神经阻滞和腹横肌平面阻滞三种给药途径;皮下浸润40例接受LL10浓度递增(4 ml,七个队列),股神经阻滞30例接受LL10浓度递增(20 ml,六个队列),腹横肌平面阻滞49例接受1.26%/0.325% LL10容量递增(25-55 ml,七个队列),每个LL10队列含安慰剂对照(n=20)。
主要发现
- 137例入组受试者均未发生严重不良事件。
- 腹横肌平面阻滞后观察到剂量依赖性全身不良事件,包括头晕、口周及舌麻木和心血管症状,均自行缓解。
- LL10呈线性药代动力学。
- 1.26%/0.325% LL10在股神经阻滞中较左布比卡因0.325%延长阻滞持续时间(中位数25.0 [21.8-29.5] h vs 15.5 [6.0-21.2] h;P = 0.021)。
关键数值与推荐
- 健康志愿者耐受1.26%/0.325% LL10剂量可达40 ml(相当于7/1.81 mg kg-1)。
- 股神经阻滞中1.26%/0.325% LL10阻滞持续时间中位数25.0 h(21.8-29.5),左布比卡因0.325%为15.5 h(6.0-21.2),P = 0.021。
临床怎么用
- LL10在股神经阻滞中可能提供较左布比卡因更长的术后镇痛持续时间,但皮下浸润和腹横肌平面阻滞未见优势。
- 腹横肌平面阻滞使用LL10时需关注剂量依赖性全身不良事件(头晕、口周及舌麻木、心血管症状),尽管本研究中均自行缓解。
局限性
- 本研究为I期单中心健康志愿者试验,样本量有限,结论需进一步临床验证。
- 原文未报告盲法设计、随机化方法及统计效能等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: LL10 is a novel long-acting local anaesthetic composed of QX-OH 1.26% and levobupivacaine hydrochloride 0.325%. This first-in-human trial assessed the safety, tolerability, efficacy, and pharmacokinetic profile of LL10. METHODS: We investigated three administration routes: s.c. infiltration, femoral nerve block (FNB), and transversus abdominis plane block (TAPB), with levobupivacaine as a positive control (n=18 total, six per route). For s.c. infiltration, 40 subjects received concentration escalation of LL10 (4 ml, seven cohorts); for FNB, 30 received LL10 at escalating concentrations (20 ml, six cohorts); and for TAPB, 49 received 1.26%/0.325% LL10 at escalating volumes (25-55 ml, seven cohorts). Each LL10 cohort included a placebo control (n=20). Safety evaluations included vital signs, adverse events (AEs), physical examinations, and laboratory tests. Sensory block was evaluated using pinprick, mechanical pain thresholds, and transcutaneous electrical stimulation. Motor block was evaluated via lower limb muscle strength grading. Plasma pharmacokinetics of QX-OH and levobupivacaine were investigated. RESULTS: None of the 137 enrolled subjects developed severe AEs. Dose-dependent systemic AEs including dizziness, perioral and tongue numbness, and cardiovascular symptoms were observed after TAPB; all resolved spontaneously. LL10 showed linear pharmacokinetics. The 1.26%/0.325% LL10 demonstrated prolonged FNB duration compared with levobupivacaine 0.325% (median, 25.0 [21.8-29.5] h vs 15.5 [6.0-21.2] h; P = 0.021). CONCLUSIONS: The 1.26%/0.325% LL10 was tolerated in healthy volunteers at doses up to 40 ml (equivalent to 7/1.81 mg kg-1). LL10 produced prolonged local anaesthesia in FNB compared with levobupivacaine 0.325%, but not in s.c. infiltration or transversus abdominus plane block. CLINICAL TRIAL REGISTRATION: ChiCTR2200064437 (Chinese Clinical Trial Registry).
引用
- Fang L, Liu J, Xu M, et al. Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic. Br J Anaesth. 2025. PMID: 41444083. doi:10.1016/j.bja.2025.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。